U.S. Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow (NGS Pre-Sequencing, Sequencing, NGS Data Analysis, Primary, Secondary & Tertiary Data Analysis), By End Use (Academic & Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities) And Trend Analysis From 2013 To 2024
U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53 billion by 2024, according to a new report by Grand View Research, Inc. Application of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of cancer.
Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost growth of this vertical throughout the forecast period.
Moreover, exponentially decreasing costs for sequencing have also spurred the demand for NGS platform in clinical oncology research as whole genome analysis has become affordable even by the smaller R&D entities. In addition, high competition amongst prominent market players to enhance their share in the market is also expected to translate into increased revenues generated by these companies as a result.
Further key findings from the report suggest:
Out of the different technologies offered by NGS platforms, targeted sequencing & resequencing accounted for the largest share owing to the fact that it enables study of changes in diseases at molecular level, & analyze the underlying modifications in the genetic sequence to investigate epigenomics of cancer, thus enhancing demand for more advancement in targeted sequencing tools.
Workflow associated with genomic sequencing is expected to witness lucrative progress as a result of variation in platforms provided by prominent market players with respect to amount of DNA sequenced per cycle, read length, and runtime. Furthermore, data analysis of raw sequence data thus obtained, is the most critical step in the workflow of NGS, and is thus anticipated to experience immense growth in coming years as a consequence of abundance of data generated post sequencing.
Adoption of high throughput sequencing platform by clinical sector is observed to be more promising for NGS based oncology research market as a consequence of usage of NGS in cancer research and more specifically in discovery of new cancer related genes, tumor heterogeneity, and identification of alterations that are contributive in tumorogenesis
Key players operating in this industry include Illumina Inc., Roche, Agilent Technologies, Knome Incorporated. Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd, Macrogen Inc., Life technologies Corp, DNASTAR Inc, Exosome Diagnostics, Biomatters Ltd, CLC Bio, BGI, Qiagen NV, Perkin Elmer, Incorporated, Pacific Bioscience, Inc, Partek, Inc, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences and Myriad Genetics and they are actively engaged in manufacturing and commercialization of innovative bioinformatics algorithms as demonstrated by the increasingly growing number of partnerships between prominent players and emerging players.
For instance, In February 2016, Thermo Fisher collaborated with Invivoscribe Technologies, Inc for the development of NGS based, in vitro diagnostic (IVD) oncology tests on Ion PGM Dx System which is further anticipated to accelerate growth of the company in near future. Similarly, in June 2016, Thermo Fisher supported enhancement and commercialization of clinical research assay and in vitro diagnostics using NGS technology launched the Ion Torrent Developers Alliance Program.
Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost growth of this vertical throughout the forecast period.
Moreover, exponentially decreasing costs for sequencing have also spurred the demand for NGS platform in clinical oncology research as whole genome analysis has become affordable even by the smaller R&D entities. In addition, high competition amongst prominent market players to enhance their share in the market is also expected to translate into increased revenues generated by these companies as a result.
Further key findings from the report suggest:
Out of the different technologies offered by NGS platforms, targeted sequencing & resequencing accounted for the largest share owing to the fact that it enables study of changes in diseases at molecular level, & analyze the underlying modifications in the genetic sequence to investigate epigenomics of cancer, thus enhancing demand for more advancement in targeted sequencing tools.
Workflow associated with genomic sequencing is expected to witness lucrative progress as a result of variation in platforms provided by prominent market players with respect to amount of DNA sequenced per cycle, read length, and runtime. Furthermore, data analysis of raw sequence data thus obtained, is the most critical step in the workflow of NGS, and is thus anticipated to experience immense growth in coming years as a consequence of abundance of data generated post sequencing.
Adoption of high throughput sequencing platform by clinical sector is observed to be more promising for NGS based oncology research market as a consequence of usage of NGS in cancer research and more specifically in discovery of new cancer related genes, tumor heterogeneity, and identification of alterations that are contributive in tumorogenesis
Key players operating in this industry include Illumina Inc., Roche, Agilent Technologies, Knome Incorporated. Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd, Macrogen Inc., Life technologies Corp, DNASTAR Inc, Exosome Diagnostics, Biomatters Ltd, CLC Bio, BGI, Qiagen NV, Perkin Elmer, Incorporated, Pacific Bioscience, Inc, Partek, Inc, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences and Myriad Genetics and they are actively engaged in manufacturing and commercialization of innovative bioinformatics algorithms as demonstrated by the increasingly growing number of partnerships between prominent players and emerging players.
For instance, In February 2016, Thermo Fisher collaborated with Invivoscribe Technologies, Inc for the development of NGS based, in vitro diagnostic (IVD) oncology tests on Ion PGM Dx System which is further anticipated to accelerate growth of the company in near future. Similarly, in June 2016, Thermo Fisher supported enhancement and commercialization of clinical research assay and in vitro diagnostics using NGS technology launched the Ion Torrent Developers Alliance Program.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information procurement
1.2 Data Analysis
CHAPTER 2 EXECUTIVE SUMMARY
2.1 U.S.
2.1.1 U.S. next generation sequencing market, 2013 - 2024 (USD Million)
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS & SCOPE
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Exponentially decreasing costs for genetic sequencing
4.1.1.2 Growing related advancement of personalized medicine
4.1.1.3 Rise in competition amongst prominent market entities
4.1.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
4.1.1.5 Increasing prevalence of cancer
4.1.1.6 Growing adoption of NGS over single gene testing
4.1.2 Market Restraint Analysis
4.1.2.1 Lack of computational efficiency for data management
4.1.2.2 Non-value based NGS reimbursement policy
4.2 Penetration & growth prospect mapping for applications, 2015
4.3 Penetration & growth prospect mapping for prominent industry players, 2015
4.4 NGS platform positioning, 2015
4.5 U.S. clinical oncology NGS company market share analysis, 2015
4.6 Next Generation Sequencing - SWOT Analysis, By Factor (political & legal, economic and technological)
4.7 Industry Analysis - Porter’s
4.8 Upcoming Developments Analysis in Oncology NGS
CHAPTER 5 MARKET CATEGORIZATION 1: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1 U.S. clinical oncology NGSmarket: Technology movement analysis
5.2 Targeted Sequencing & Resequencing
5.2.1 U.S. targeted sequencing & resequencingmarket, 2013 - 2024 (USD Million)
5.3 Whole Genome Sequencing
5.3.1 U.S. whole genome sequencingmarket, 2013 - 2024 (USD Million)
5.4 Whole Exome Sequencing
5.4.1 U.S. whole exomesequencing market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: WORKFLOW ESTIMATES & TREND ANALYSIS
6.1 U.S. clinical oncology NGS market: Workflow movement analysis
6.2 NGS Pre-Sequencing
6.2.1 U.S.NGS pre-sequencingmarket, 2013 - 2024 (USD Million)
6.3 NGS Sequencing
6.3.1 U.S.NGS sequencingmarket, 2013 - 2024 (USD Million)
6.4 NGS Data Analysis
6.4.1 U.S. NGS data analysis2013 - 2024 (USD Million)
6.4.2 NGS Primary Data Analysis
6.4.2.1 U.S.NGS primary data analysis market, 2013 - 2024 (USD Million)
6.4.3 NGS Secondary Data Analysis
6.4.3.1 U.S.NGS secondary data analysis, 2013 - 2024 (USD Million)
6.4.4 NGS Tertiary Data Analysis
6.4.4.1 U.S.NGS tertiary data analysisservices market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: END-USE ESTIMATES & TREND ANALYSIS
7.1 U.S. Clinical Oncology NGSmarket: End-use movement analysis
7.2 Academic Research
7.2.1 U.S.academic researchmarket, 2013 - 2024 (USD Million)
7.3 Clinical Research
7.3.1 U.S.clinical researchmarket, 2013 - 2024 (USD Million)
7.4 Hospitals & Clinics
7.4.1 U.S.hospitals & clinics market2013 - 2024 (USD Million)
7.5 Pharma & Biotech Entities
7.5.1 U.S.pharma & biotech entitiesmarket, 2013 - 2024 (USD Million)
7.6 Other users
7.6.1 U.S.other usersmarket, 2013 - 2024 (USD Million)
CHAPTER 8 MARKET CATEGORIZATION 4: REGIONAL ESTIMATES & TREND ANALYSIS, BY TECHNOLOGY, WORKFLOW & END-USE
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles
9.3.1 Illumina Incorporated
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Roche Sequencing (454 Life Sciences)
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Agilent Technologies
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 Knome Inc.
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Genomatix Software GmbH
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 GATC Biotech Ag
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Oxford Nanopore Technologies Ltd.
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Macrogen Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Life Technologies Corp.
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 DNASTAR Inc.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Myriad Genetics
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Exosome Diagnostics, Inc.
9.3.12.1 Company Overview
9.3.12.2 Financial Performance
9.3.12.3 Product Benchmarking
9.3.12.4 Strategic Initiatives
9.3.13 Biomatters Ltd.
9.3.13.1 Company Overview
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 Life CLC Bio
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 BGI (Complete Genomics)
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 Qiagen NV
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives
9.3.17 Perkin Elmer, Inc.
9.3.17.1 Company Overview
9.3.17.2 Financial Performance
9.3.17.3 Product Benchmarking
9.3.17.4 Strategic Initiatives
9.3.18 Pacific Bioscience, Inc.
9.3.18.1 Company Overview
9.3.18.2 Financial Performance
9.3.18.3 Product Benchmarking
9.3.18.4 Strategic Initiatives
9.3.19 Partek, Inc.
9.3.19.1 Company Overview
9.3.19.2 Financial Performance
9.3.19.3 Product Benchmarking
9.3.19.4 Strategic Initiatives
9.3.20 GnuBIO (Bio-Rad)
9.3.20.1 Company Overview
9.3.20.2 Financial Performance
9.3.20.3 Product Benchmarking
9.3.20.4 Strategic Initiatives
9.3.21 Foundation Medicine Inc.
9.3.21.1 Company Overview
9.3.21.2 Financial Performance
9.3.21.3 Product Benchmarking
9.3.21.4 Strategic Initiatives
9.3.22 Paradigm Diagnostics, Inc
9.3.22.1 Company Overview
9.3.22.2 Financial Performance
9.3.22.3 Product Benchmarking
9.3.22.4 Strategic Initiatives
9.3.23 Caris Life Sciences
9.3.23.1 Company Overview
9.3.23.2 Financial Performance
9.3.23.3 Product Benchmarking
9.3.23.4 Strategic Initiatives
1.1 Information procurement
1.2 Data Analysis
CHAPTER 2 EXECUTIVE SUMMARY
2.1 U.S.
2.1.1 U.S. next generation sequencing market, 2013 - 2024 (USD Million)
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS & SCOPE
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Exponentially decreasing costs for genetic sequencing
4.1.1.2 Growing related advancement of personalized medicine
4.1.1.3 Rise in competition amongst prominent market entities
4.1.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
4.1.1.5 Increasing prevalence of cancer
4.1.1.6 Growing adoption of NGS over single gene testing
4.1.2 Market Restraint Analysis
4.1.2.1 Lack of computational efficiency for data management
4.1.2.2 Non-value based NGS reimbursement policy
4.2 Penetration & growth prospect mapping for applications, 2015
4.3 Penetration & growth prospect mapping for prominent industry players, 2015
4.4 NGS platform positioning, 2015
4.5 U.S. clinical oncology NGS company market share analysis, 2015
4.6 Next Generation Sequencing - SWOT Analysis, By Factor (political & legal, economic and technological)
4.7 Industry Analysis - Porter’s
4.8 Upcoming Developments Analysis in Oncology NGS
CHAPTER 5 MARKET CATEGORIZATION 1: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1 U.S. clinical oncology NGSmarket: Technology movement analysis
5.2 Targeted Sequencing & Resequencing
5.2.1 U.S. targeted sequencing & resequencingmarket, 2013 - 2024 (USD Million)
5.3 Whole Genome Sequencing
5.3.1 U.S. whole genome sequencingmarket, 2013 - 2024 (USD Million)
5.4 Whole Exome Sequencing
5.4.1 U.S. whole exomesequencing market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: WORKFLOW ESTIMATES & TREND ANALYSIS
6.1 U.S. clinical oncology NGS market: Workflow movement analysis
6.2 NGS Pre-Sequencing
6.2.1 U.S.NGS pre-sequencingmarket, 2013 - 2024 (USD Million)
6.3 NGS Sequencing
6.3.1 U.S.NGS sequencingmarket, 2013 - 2024 (USD Million)
6.4 NGS Data Analysis
6.4.1 U.S. NGS data analysis2013 - 2024 (USD Million)
6.4.2 NGS Primary Data Analysis
6.4.2.1 U.S.NGS primary data analysis market, 2013 - 2024 (USD Million)
6.4.3 NGS Secondary Data Analysis
6.4.3.1 U.S.NGS secondary data analysis, 2013 - 2024 (USD Million)
6.4.4 NGS Tertiary Data Analysis
6.4.4.1 U.S.NGS tertiary data analysisservices market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: END-USE ESTIMATES & TREND ANALYSIS
7.1 U.S. Clinical Oncology NGSmarket: End-use movement analysis
7.2 Academic Research
7.2.1 U.S.academic researchmarket, 2013 - 2024 (USD Million)
7.3 Clinical Research
7.3.1 U.S.clinical researchmarket, 2013 - 2024 (USD Million)
7.4 Hospitals & Clinics
7.4.1 U.S.hospitals & clinics market2013 - 2024 (USD Million)
7.5 Pharma & Biotech Entities
7.5.1 U.S.pharma & biotech entitiesmarket, 2013 - 2024 (USD Million)
7.6 Other users
7.6.1 U.S.other usersmarket, 2013 - 2024 (USD Million)
CHAPTER 8 MARKET CATEGORIZATION 4: REGIONAL ESTIMATES & TREND ANALYSIS, BY TECHNOLOGY, WORKFLOW & END-USE
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles
9.3.1 Illumina Incorporated
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Roche Sequencing (454 Life Sciences)
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Agilent Technologies
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 Knome Inc.
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Genomatix Software GmbH
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 GATC Biotech Ag
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Oxford Nanopore Technologies Ltd.
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Macrogen Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Life Technologies Corp.
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 DNASTAR Inc.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Myriad Genetics
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Exosome Diagnostics, Inc.
9.3.12.1 Company Overview
9.3.12.2 Financial Performance
9.3.12.3 Product Benchmarking
9.3.12.4 Strategic Initiatives
9.3.13 Biomatters Ltd.
9.3.13.1 Company Overview
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 Life CLC Bio
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 BGI (Complete Genomics)
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 Qiagen NV
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives
9.3.17 Perkin Elmer, Inc.
9.3.17.1 Company Overview
9.3.17.2 Financial Performance
9.3.17.3 Product Benchmarking
9.3.17.4 Strategic Initiatives
9.3.18 Pacific Bioscience, Inc.
9.3.18.1 Company Overview
9.3.18.2 Financial Performance
9.3.18.3 Product Benchmarking
9.3.18.4 Strategic Initiatives
9.3.19 Partek, Inc.
9.3.19.1 Company Overview
9.3.19.2 Financial Performance
9.3.19.3 Product Benchmarking
9.3.19.4 Strategic Initiatives
9.3.20 GnuBIO (Bio-Rad)
9.3.20.1 Company Overview
9.3.20.2 Financial Performance
9.3.20.3 Product Benchmarking
9.3.20.4 Strategic Initiatives
9.3.21 Foundation Medicine Inc.
9.3.21.1 Company Overview
9.3.21.2 Financial Performance
9.3.21.3 Product Benchmarking
9.3.21.4 Strategic Initiatives
9.3.22 Paradigm Diagnostics, Inc
9.3.22.1 Company Overview
9.3.22.2 Financial Performance
9.3.22.3 Product Benchmarking
9.3.22.4 Strategic Initiatives
9.3.23 Caris Life Sciences
9.3.23.1 Company Overview
9.3.23.2 Financial Performance
9.3.23.3 Product Benchmarking
9.3.23.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 Healthcare expenditure levels, 2012
TABLE 2 North America cancer incidences in 2012
TABLE 3 U.S. clinical oncology NGS market estimates, by technology, 2013 - 2015 (USD Million)
TABLE 4 U.S. clinical oncology NGS market forecasts, by technology, 2016 - 2024 (USD Million)
TABLE 5 U.S. clinical oncology NGS market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 6 U.S. clinical oncology NGS market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 7 U.S. clinical oncology NGS data analysis market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 8 U.S. clinical oncology NGS data analysis market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 9 U.S. clinical oncology NGS market estimates, by end use, 2013 - 2015 (USD Million)
TABLE 10 U.S. clinical oncology NGS market forecasts, by end use, 2016- 2024 (USD Million)
TABLE 1 Healthcare expenditure levels, 2012
TABLE 2 North America cancer incidences in 2012
TABLE 3 U.S. clinical oncology NGS market estimates, by technology, 2013 - 2015 (USD Million)
TABLE 4 U.S. clinical oncology NGS market forecasts, by technology, 2016 - 2024 (USD Million)
TABLE 5 U.S. clinical oncology NGS market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 6 U.S. clinical oncology NGS market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 7 U.S. clinical oncology NGS data analysis market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 8 U.S. clinical oncology NGS data analysis market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 9 U.S. clinical oncology NGS market estimates, by end use, 2013 - 2015 (USD Million)
TABLE 10 U.S. clinical oncology NGS market forecasts, by end use, 2016- 2024 (USD Million)
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 U.S. next generation sequencing market, 2013 - 2024 (USDMillion)
FIG. 8 Market summary
FIG. 9 Market trends & outlook
FIG. 10 Market segmentation & scope
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Cost per raw mega base (Mb) of DNA sequence (USD)
FIG. 13 Cost per genome
FIG. 14 Expected rise in expenditure for cancer treatment (USD Billion)
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 Penetration & growth prospect mapping for applications, 2015
FIG. 17 Penetration & growth prospect mapping for prominent industry players, 2015
FIG. 18 NGS platform positioning, 2015
FIG. 19 U.S. clinical oncology NGS company market share analysis, 2015
FIG. 20 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 21 Porter’s Five Forces Analysis
FIG. 22 U.S. clinical oncology NGS market:Technology outlook key takeaways
FIG. 23 U.S. clinical oncology NGS market: Technology movement analysis
FIG. 24 U.S.targeted sequencing & resequencing market, 2013 - 2024 (USD Million)
FIG. 25 U.S. whole genome sequencing market, 2013 - 2024 (USD Million)
FIG. 26 U.S. whole exome sequencing market, 2013 - 2024 (USD Million)
FIG. 27 U.S. clinical oncology NGS market workflow outlook key takeaways
FIG. 28 Next generation sequencing market: workflow movement analysis
FIG. 29 U.S. NGS pre-sequencingmarket, 2013 - 2024 (USD Million)
FIG. 30 U.S. NGS Sequencingmarket, 2013 - 2024 (USD Million)
FIG. 31 U.S. NGS data analysismarket, 2013 - 2024 (USD Million)
FIG. 32 U.S. NGS primary data analysis market, 2013 - 2024 (USD Million)
FIG. 33 U.S. NGS secondary data analysis market, 2013 - 2024 (USD Million)
FIG. 34 U.S. NGS tertiary data analysis market, 2013 - 2024 (USD Million)
FIG. 35 U.S. clinical oncology NGS market end-use outlook key takeaways
FIG. 36 Next generation sequencing market: End-use movement analysis
FIG. 37 U.S. academic research market, 2013 - 2024 (USD Million)
FIG. 38 U.S. clinical research market, 2013 - 2024 (USD Million)
FIG. 39 U.S. hospitals & clinics market, 2013 - 2024 (USD Million)
FIG. 40 U.S. pharma & biotech entities market, 2013 - 2024 (USD Million)
FIG. 41 U.S. other users market, 2013 - 2024 (USD Million)
FIG. 42 Strategy framework
FIG. 43 Participant categorization
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 U.S. next generation sequencing market, 2013 - 2024 (USDMillion)
FIG. 8 Market summary
FIG. 9 Market trends & outlook
FIG. 10 Market segmentation & scope
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Cost per raw mega base (Mb) of DNA sequence (USD)
FIG. 13 Cost per genome
FIG. 14 Expected rise in expenditure for cancer treatment (USD Billion)
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 Penetration & growth prospect mapping for applications, 2015
FIG. 17 Penetration & growth prospect mapping for prominent industry players, 2015
FIG. 18 NGS platform positioning, 2015
FIG. 19 U.S. clinical oncology NGS company market share analysis, 2015
FIG. 20 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 21 Porter’s Five Forces Analysis
FIG. 22 U.S. clinical oncology NGS market:Technology outlook key takeaways
FIG. 23 U.S. clinical oncology NGS market: Technology movement analysis
FIG. 24 U.S.targeted sequencing & resequencing market, 2013 - 2024 (USD Million)
FIG. 25 U.S. whole genome sequencing market, 2013 - 2024 (USD Million)
FIG. 26 U.S. whole exome sequencing market, 2013 - 2024 (USD Million)
FIG. 27 U.S. clinical oncology NGS market workflow outlook key takeaways
FIG. 28 Next generation sequencing market: workflow movement analysis
FIG. 29 U.S. NGS pre-sequencingmarket, 2013 - 2024 (USD Million)
FIG. 30 U.S. NGS Sequencingmarket, 2013 - 2024 (USD Million)
FIG. 31 U.S. NGS data analysismarket, 2013 - 2024 (USD Million)
FIG. 32 U.S. NGS primary data analysis market, 2013 - 2024 (USD Million)
FIG. 33 U.S. NGS secondary data analysis market, 2013 - 2024 (USD Million)
FIG. 34 U.S. NGS tertiary data analysis market, 2013 - 2024 (USD Million)
FIG. 35 U.S. clinical oncology NGS market end-use outlook key takeaways
FIG. 36 Next generation sequencing market: End-use movement analysis
FIG. 37 U.S. academic research market, 2013 - 2024 (USD Million)
FIG. 38 U.S. clinical research market, 2013 - 2024 (USD Million)
FIG. 39 U.S. hospitals & clinics market, 2013 - 2024 (USD Million)
FIG. 40 U.S. pharma & biotech entities market, 2013 - 2024 (USD Million)
FIG. 41 U.S. other users market, 2013 - 2024 (USD Million)
FIG. 42 Strategy framework
FIG. 43 Participant categorization
